Publications by authors named "Jonathan Bullman"

Claim this Profile
T
The effects of GSK2981710, a medium-chain triglyceride, on cognitive function in healthy older participants: A randomised, placebo-controlled study.
Barry V O'Neill, Chris M Dodds, Sam R Miller, Ashutosh Gupta, Philip Lawrence, Jonathan Bullman

Hum Psychopharmacol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti-CD3ε mAb in new-onset type 1 diabetes mellitus patients.
Georgios Vlasakakis, Antonella Napolitano, Ruth Barnard, Kim Brown, Jonathan Bullman

Br J Clin Pharmacol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjustment of the area under the concentration curve by terminal rate constant for bioequivalence assessment in a parallel-group study of lamotrigine.
Jiansong Yang, Peiming Ma, Jonathan Bullman, Andrew Nicholls, Chao Chen

Br J Clin Pharmacol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study.
Robert Bissonnette, Lakshmi S Vasist, Jonathan N Bullman, Therese Collingwood, Geng Chen

Clin Pharmacol Drug Dev· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Vincent Meininger, Angela Genge, Leonard H van den Berg, Wim Robberecht, Albert Ludolph, Jonathan Bullman

Lancet Neurol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The relative bioavailability of 2 prototype fixed-dose combination formulations for amlodipine and rosuvastatin in healthy white and Chinese subjects.
Htar H Nwe, Jonathan N Bullman, Shashidhar M Joshi, Annie Stylianou, Shiva G Kapsi

Clin Pharmacol Drug Dev· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ozanezumab dose selection for amyotrophic lateral sclerosis by pharmacokinetic-pharmacodynamic modelling of immunohistochemistry data from patient muscle biopsies.
Alienor Berges, Jonathan Bullman, Stewart Bates, David Krull, Nicola Williams

PLoS One· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of hemodialysis on pharmacokinetics of ezogabine/retigabine and its N-acetyl metabolite in patients with end stage renal disease.
Debra J Tompson, Mauro Buraglio, Jonathan Bullman, Christopher S Crean, Kirsty Rayner

Curr Clin Pharmacol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, placebo-controlled trial of the analgesic efficacy and safety of the p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain from lumbosacral radiculopathy.
Thor Ostenfeld, Alok Krishen, Robert Y Lai, Jonathan Bullman, Joanne Green

Clin J Pain· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial.
Vincent Meininger, Pierre-François Pradat, Andrea Corse, Safa Al-Sarraj, Benjamin Rix Brooks, Jonathan Bullman

PLoS One· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PET.
Khanum Ridler, Roger N Gunn, Graham E Searle, Julien Barletta, Jan Passchier, Jonathan N Bullman

J Psychopharmacol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.
Erik T te Beek, Justin L Hay, Jonathan N Bullman, Clare Burgess, Kimberly J Nahon

Br J Clin Pharmacol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human microdose evaluation of the novel EP1 receptor antagonist GSK269984A.
Thor Ostenfeld, Claire Beaumont, Jonathan Bullman, Maria Beaumont, Phillip Jeffrey

Br J Clin Pharmacol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, controlled study to investigate the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166, ibuprofen or placebo in patients with acute pain following third molar tooth extraction.
Thor Ostenfeld, Jeffrey Price, Massimo Albanese, Jonathan Bullman, Fiona Guillard

Clin J Pain· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers.
Jonathan Bullman, Andrew Nicholls, Kevan Van Landingham, Richard Fleck, Alain Vuong

Epilepsia· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans.
Boris A Chizh, Mary B O'Donnell, Antonella Napolitano, Jie Wang, Allison C Brooke, Jonathan N Bullman

Pain· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects.
Jagdev Sidhu, Sarah Job, Jonathan Bullman, Emma Francis, Richard Abbott

Br J Clin Pharmacol· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine.
Jochen G W Theis, Jagdev Sidhu, Joanne Palmer, Sarah Job, Jonathan Bullman

Neuropsychopharmacology· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers.
Christine Walls, Anastasia Lewis, Jonathan Bullman, Diane Boswell, Simon J Summers

Curr Med Res Opin· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis